Newly developed drugs, diagnostics, vaccines and insecticides will have an impact only when they reach the people who need them.
After health products are developed for low and middle income settings, access is not automatic; it requires active and timely management of multiple issues, including manufacturing, economics and financing, pricing, intellectual property, regulatory approval, global policy, and country decision making. In addition, field realities must constantly feed back into the research and development process so that products that are designed are addressing real needs and can function effectively in resource-constrained environments.
Staff at product development partnerships (PDPs), donors, pharmaceutical companies, Ministries of Health and civil society organizations, and others who are involved in creating access to products, need a wide range of information to do this work effectively.
This site has been developed by the PDP Access Group for the exchange of information so that all partners can maximize the potential for appropriate new products — well delivered — to improve global health dramatically.
These are the latest in a series of discussion papers commissioned by the PDP Access Steering Committee.
Click for presentations, agenda, and final the meeting report
Click for agenda, presentations, and the final meeting report